This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Regeneron Pharmaceuticals, Inc.. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Kei Saotome: Innovator in Antibody Development
Introduction
Kei Saotome is a prominent inventor based in Englewood, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on innovative solutions for treating diseases associated with the TMPRSS6 protein.
Latest Patents
Kei Saotome holds a patent for "Anti-TMPRSS6 antibodies and uses thereof." This patent includes monoclonal antibodies that specifically bind to the transmembrane serine protease 6 (TMPRSS6) protein. The disclosed antibodies are fully human and have potential applications in treating or preventing various diseases, disorders, or conditions linked to TMPRSS6 in humans.
Career Highlights
Kei Saotome is currently associated with Regeneron Pharmaceuticals, Inc., where he continues to advance his research in antibody development. His expertise in this area has positioned him as a key player in the biotechnology sector.
Collaborations
Some of his notable coworkers include Sarah Jane Hatsell and Heinrich Emil Lob. Their collaborative efforts contribute to the innovative research environment at Regeneron Pharmaceuticals.
Conclusion
Kei Saotome's work in developing anti-TMPRSS6 antibodies exemplifies the impact of innovative research in biotechnology. His contributions are paving the way for new therapeutic approaches to combat diseases associated with TMPRSS6.